Get notified of page updates

Search Results: Treatment + Endometrial Cancer (9 results)

New Search
PRINTER FRIENDLY PAGE 1 through 9 of 9

Treatment
Treatment study for people with advanced or metastatic cancers

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.

Clinicaltrials.gov identifier: NCT06974110

Treatment
Treatment study for people with previously treated endometrial cancer

Study of an Investigational Drug, E7386 Plus Lenvatinib in People with Endometrial Cancer after Chemotherapy and Immunotherapy

This trial will evaluate the optimal dose, safety and effectiveness of an investigational drug called E7386 given together with a targeted therapy called lenvatinib.

Clinicaltrials.gov identifier: NCT04008797

Treatment
Treatment study for people with advanced or metastatic solid tumors

Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs

The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor. 

Clinicaltrials.gov identifier: NCT06167317

Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations

Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation

The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.

Clinicaltrials.gov identifier: NCT05887492

Treatment
People with stage I endometrial cancer who are having a hysterectomy

Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.

Clinicaltrials.gov identifier: NCT05646316

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas

This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas. 

Clinicaltrials.gov identifier: NCT06022029

Treatment
This study is for people with recurrent endometrial cancer

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.

 

Clinicaltrials.gov identifier: NCT04486352
ASCO TAPUR: Targeted Agent and Profiling Utilization Registry Study.

Treatment
Cancer treatment study for people with advanced solid tumors

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Clinicaltrials.gov identifier: NCT02693535

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

Clinicaltrials.gov identifier: NCT03607890
Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
69 results
Clinical Trial Official Title
NCT06855706 An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
NCT06463028 Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT07216105 FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT06989112 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06538337 Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
NCT05646316 Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT06993844 Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06366347 ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
NCT03785288 Vaginal Cuff Brachytherapy Fractionation Study
NCT04104776 A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT06974110 Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT03968406 Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT04570553 Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT06400472 A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT05112601 Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT04774419 Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
NCT05799274 Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT05123482 A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT07120945 Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
NCT07220512 The Better, Harder, Faster, Stronger Study
NCT04567771 Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT03422198 Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT06746428 Activity Coaching During Pelvic Radiation Therapy
NCT05049538 Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
NCT05768139 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05059444 ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05520099 Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05797831 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05277051 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05051722 Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT04586959 Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT05712668 Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT04704661 Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT07044336 Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT05256225 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT04839614 Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT05691504 Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05592626 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05990426 Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT05564377 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT04291612 Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT05603910 Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT06677112 MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT04997096 Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT03564340 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT05150691 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05554328 Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT06253494 Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT05640999 Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT06686043 HPV Vaccine, Imiquimod, and Metformin Combination Trial
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT05489211 Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05086692 A Beta-only IL-2 ImmunoTherapY Study
NCT04683653 Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT05691010 A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT05867251 Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT04512144 Mindfulness in Endometrial and Cervical Cancer
NCT06877572 Weight Loss Management in Endometrial Cancer Survivors
NCT06349642 Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
NCT05758688 PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT05797168 Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT06096688 Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT04485013 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT06129604 Pilot Window of Opportunity Trial (POET)
NCT00005095 Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT05819892 Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT04851119 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Sponsored By